Atossa lures Carbonaro with $1.1m stock option
This article was originally published in Clinica
Executive Summary
Atossa Genetics, a developer of breast cancer predictive tests, has appointed Peter Carbonaro to the newly created role of senior vice-president of operations. Mr Carbonaro will be responsible for the following functions at Atossa: regulatory, quality, manufacturing, supply chain, IT, facilities and human resources. He brings to the company over 30 years’ experience in the medtech/biotech industry, and has worked for companies such as Gilead Sciences, Roche and several early-stage firms. Seattle, Washington-based Atossa disclosed that Mr Carbonaro had been awarded an option to purchase a total of 250,000 share of Atossa stock, with an exercise price equivalent to $4.58 per share. This gives the option a total value of $1.14 million – which may have helped lure him.